FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137625384> ?p ?o ?g. }

• W2137625384 endingPage "585" @default.
• W2137625384 startingPage "573" @default.
• W2137625384 abstract "Lixisenatide is a potent, selective and short-acting once daily prandial glucagon-like peptide-1 receptor agonist which lowers glycohemoglobin and body weight by clinically significant amounts in patients with type 2 diabetes treated with basal insulin, with limited risk of hypoglycemia.To assess the cost-effectiveness of lixisenatide versus bolus insulin, both in combination with basal insulin, in patients with type 2 diabetes in Norway.The IMS CORE Diabetes Model, a non-product-specific and validated simulation model, was used to make clinical and cost projections. Transition probabilities, risk adjustments and the progression of complication risk factors were derived from the UK Prospective Diabetes Study, supplemented with Norwegian data. Patients were assumed to receive combination treatment with basal insulin, lixisenatide or bolus insulin therapy for 3 years, followed by intensification of a basal-bolus insulin regimen for their remaining lifetime. Simulated healthcare costs, taken from the public payer perspective, were derived from microcosting and diagnosis related groups, discounted at 4% per annum and reported in Norwegian krone (NOK). Productivity costs were also captured based on extractions from the Norwegian Labor and Welfare Administration. Health state utilities were derived from a systematic literature review. Sensitivity and scenario analyses were performed.Lixisenatide in combination with basal insulin was associated with increased quality-adjusted life years (QALYs) and reduced lifetime healthcare costs compared to bolus insulin in combination with basal insulin in patients with Type 2 diabetes, and can be considered dominant. The net monetary benefit of lixisenatide versus bolus insulin was NOK 39,369 per patient. Results were sensitive to discounting, the application of excess body weight associated disutility and uncertainty surrounding the changes in HbA1c.Lixisenatide may be considered an economically efficient therapy in combination with basal insulin in the Norwegian setting, due to cost savings, weight loss and associated gains in health-related quality of life." @default.
• W2137625384 created "2016-06-24" @default.
• W2137625384 creator A5009451018 @default.
• W2137625384 creator A5011746123 @default.
• W2137625384 creator A5017619631 @default.
• W2137625384 creator A5017811986 @default.
• W2137625384 creator A5024658365 @default.
• W2137625384 creator A5068129794 @default.
• W2137625384 date "2015-06-01" @default.
• W2137625384 modified "2023-09-26" @default.
• W2137625384 title "Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway" @default.
• W2137625384 cites W1577650798 @default.
• W2137625384 cites W1766458629 @default.
• W2137625384 cites W1972187673 @default.
• W2137625384 cites W1977102586 @default.
• W2137625384 cites W1977962529 @default.
• W2137625384 cites W1985123503 @default.
• W2137625384 cites W1996441843 @default.
• W2137625384 cites W2005947177 @default.
• W2137625384 cites W2020572030 @default.
• W2137625384 cites W2028272916 @default.
• W2137625384 cites W2028325127 @default.
• W2137625384 cites W2032495940 @default.
• W2137625384 cites W2035613798 @default.
• W2137625384 cites W2039713231 @default.
• W2137625384 cites W2047564829 @default.
• W2137625384 cites W2056623201 @default.
• W2137625384 cites W2059338882 @default.
• W2137625384 cites W2070710390 @default.
• W2137625384 cites W2073888455 @default.
• W2137625384 cites W2075288946 @default.
• W2137625384 cites W2079089745 @default.
• W2137625384 cites W2091823111 @default.
• W2137625384 cites W20942925 @default.
• W2137625384 cites W2100376951 @default.
• W2137625384 cites W2104906866 @default.
• W2137625384 cites W2106709036 @default.
• W2137625384 cites W2108017238 @default.
• W2137625384 cites W2108165812 @default.
• W2137625384 cites W2110524240 @default.
• W2137625384 cites W2110599879 @default.
• W2137625384 cites W2118472474 @default.
• W2137625384 cites W2123946565 @default.
• W2137625384 cites W2126252058 @default.
• W2137625384 cites W2144379730 @default.
• W2137625384 cites W2150712216 @default.
• W2137625384 cites W2156365419 @default.
• W2137625384 cites W2164787130 @default.
• W2137625384 cites W2169355652 @default.
• W2137625384 cites W2170031373 @default.
• W2137625384 cites W2171109114 @default.
• W2137625384 cites W2275139239 @default.
• W2137625384 doi "https://doi.org/10.3111/13696998.2015.1038271" @default.
• W2137625384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25853868" @default.
• W2137625384 hasPublicationYear "2015" @default.
• W2137625384 type Work @default.
• W2137625384 sameAs 2137625384 @default.
• W2137625384 citedByCount "10" @default.
• W2137625384 countsByYear W21376253842015 @default.
• W2137625384 countsByYear W21376253842017 @default.
• W2137625384 countsByYear W21376253842019 @default.
• W2137625384 countsByYear W21376253842020 @default.
• W2137625384 countsByYear W21376253842021 @default.
• W2137625384 crossrefType "journal-article" @default.
• W2137625384 hasAuthorship W2137625384A5009451018 @default.
• W2137625384 hasAuthorship W2137625384A5011746123 @default.
• W2137625384 hasAuthorship W2137625384A5017619631 @default.
• W2137625384 hasAuthorship W2137625384A5017811986 @default.
• W2137625384 hasAuthorship W2137625384A5024658365 @default.
• W2137625384 hasAuthorship W2137625384A5068129794 @default.
• W2137625384 hasBestOaLocation W21376253841 @default.
• W2137625384 hasConcept C126322002 @default.
• W2137625384 hasConcept C134018914 @default.
• W2137625384 hasConcept C2776442814 @default.
• W2137625384 hasConcept C2777180221 @default.
• W2137625384 hasConcept C2779306644 @default.
• W2137625384 hasConcept C2780533449 @default.
• W2137625384 hasConcept C2780668416 @default.
• W2137625384 hasConcept C555293320 @default.
• W2137625384 hasConcept C71924100 @default.
• W2137625384 hasConceptScore W2137625384C126322002 @default.
• W2137625384 hasConceptScore W2137625384C134018914 @default.
• W2137625384 hasConceptScore W2137625384C2776442814 @default.
• W2137625384 hasConceptScore W2137625384C2777180221 @default.
• W2137625384 hasConceptScore W2137625384C2779306644 @default.
• W2137625384 hasConceptScore W2137625384C2780533449 @default.
• W2137625384 hasConceptScore W2137625384C2780668416 @default.
• W2137625384 hasConceptScore W2137625384C555293320 @default.
• W2137625384 hasConceptScore W2137625384C71924100 @default.
• W2137625384 hasIssue "8" @default.
• W2137625384 hasLocation W21376253841 @default.
• W2137625384 hasLocation W21376253842 @default.
• W2137625384 hasOpenAccess W2137625384 @default.
• W2137625384 hasPrimaryLocation W21376253841 @default.
• W2137625384 hasRelatedWork W2045993936 @default.
• W2137625384 hasRelatedWork W2057262151 @default.
• W2137625384 hasRelatedWork W2057434408 @default.
• W2137625384 hasRelatedWork W2068655959 @default.

• next